Trial
NCT04241835
A Study to Compare the Blood Levels and Safety of Tazemetostat in Participants With Advanced Cancer and Moderate/Severe Liver Impairment to Participants With Advanced Cancer and Normal Liver Function
Phase ITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Epizyme, Inc.
Collaborators
Sponsor GmbH
Condition
Hepatic Impairment
Intervention
Tazemetostat
Why stopped
Ipsen decided to discontinue all active tazemetostat clinical trials.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-04-16